Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Relapse · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab probably leads to lower number of participants experiencing ≥ 1 relapse compared with interferon beta‐1a (moderate certainty).

1 finding from 1 review

Ocrelizumab for multiple sclerosis 2022 · Cochrane Headline outcomes only
RR 0.61 [0.52, 0.73]
2 studies · 1656 participants
Moderate